Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Exclusion Criteria

• •Have clinically significant acute or chronic disease (e.g., coronary artery disease, diabetes, chronic renal insufficiency, asthma).
• •Have major surgery within eight weeks of dosing.
• •Have overt viral illness within four weeks of dosing.
• •Have tendency or history in family of tendency for bleeding.
• •Have clinically significant abnormalities on clinical laboratory tests (chemistry, hematology, urinalysis).
• •Have taken aspirin or any other non-steroidal anti-inflammatory drug (NSAID) within 10 days prior to admission to study facility.
• •Have ever taken or received any of the following for medical conditions: (antiplatelet compounds including clopidogrel, ticlopidine, dipyridamole, tirofiban, eptifibatide, abciximab, adenosine, and prostacyclin) or (anticoagulants including vitamin K antagonists, thrombin inhibitors, heparins, hirudin or related compounds, argatroban and factor Xa inhibitors)
• •Have a clinically significant ECG abnormality.